Sage Therapeutics Inc Cash Flow Conversion Efficiency
Sage Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Sage Therapeutics Inc (SAGE) has a cash flow conversion efficiency ratio of -0.159x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-58.69 Million) by net assets ($368.74 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Sage Therapeutics Inc (2012–2024)
Cash flow conversion efficiency of Sage Therapeutics Inc from 2012 to 2024. This chart illustrates how Sage Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Sage Therapeutics Inc for real-time trading data and today's change.
Sage Therapeutics Inc Cash Flow Conversion Ratio Explained
Sage Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Sage Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sage Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Sage Therapeutics Inc (SAGE) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Gongdong Medical Technology Co Ltd
SHG:605369
|
0.034x |
|
Sido Muncul PT
JK:SIDO
|
0.055x |
|
Kangping Technology (Suzhou) Co. Ltd.
SHE:300907
|
0.018x |
|
Canadian Tire Corporation Limited
TO:CTC
|
0.117x |
|
First Hi-tec Enterprise Co Ltd
TWO:5439
|
0.178x |
|
Jiangsu Liba Enterprise Joint-Stock Co Ltd
SHG:603519
|
0.057x |
|
Changzhou Almaden Co Ltd
SHE:002623
|
-0.017x |
|
Northpointe Bancshares, Inc.
NYSE:NPB
|
0.062x |
Annual Cash Flow Conversion Efficiency for Sage Therapeutics Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Sage Therapeutics Inc from 2012 to 2024. Review SAGE cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $465.09 Million | $-267.19 Million | -0.575x | +15.03% |
| 2023-12-31 | $799.53 Million | $-540.59 Million | -0.676x | -84.10% |
| 2022-12-31 | $1.25 Billion | $-460.04 Million | -0.367x | -67.91% |
| 2021-12-31 | $1.73 Billion | $-378.18 Million | -0.219x | -168.23% |
| 2020-12-31 | $2.07 Billion | $664.28 Million | 0.321x | +157.27% |
| 2019-12-31 | $944.65 Million | $-528.71 Million | -0.560x | -85.29% |
| 2018-12-31 | $862.97 Million | $-260.67 Million | -0.302x | +34.50% |
| 2017-12-31 | $475.48 Million | $-219.28 Million | -0.461x | -43.20% |
| 2016-12-31 | $368.52 Million | $-118.68 Million | -0.322x | +20.86% |
| 2015-12-31 | $173.69 Million | $-70.68 Million | -0.407x | -83.41% |
| 2014-12-31 | $121.89 Million | $-27.04 Million | -0.222x | -139.94% |
| 2013-12-31 | $-31.54 Million | $-17.52 Million | 0.555x | -16.65% |
| 2012-12-31 | $-13.39 Million | $-8.93 Million | 0.666x | -- |
About Sage Therapeutics Inc
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric m… Read more